Contents

Part I  Managing Perimenopausal and Postmenopausal Symptoms with the New Menopausal HT

1 FAQ: Definitions of Menopause and Biological Actions of Sex Steroids ................................. 3
   Introduction .................................................................. 3
   Bibliography ................................................................ 13

2 Principles of Practice .................................................. 17
   Bibliography ................................................................ 20

3 Medical Association Guidelines,
   Post-2002/Women’s Health Initiative Findings ...... 21
   FDA Approvals and Contraindications ....................... 22
   FDA Approvals for HT ............................................. 22
   FDA Contraindications for HT ................................. 22
   The North American Menopause Society ................. 23
   International Menopause Society:
       Recommendations on Postmenopausal Hormonal Therapy and Preventative Strategies for Midlife Health ................................. 24
   AACE/American Association of Clinical Endocrinology ......................................................... 34
   Bibliography ................................................................ 37
4 Perimenopausal Symptoms: Hot Flushes and Night Sweats; Sleep Disturbances; Urogenital Discomfort; Sexual Libido Issues; Mood and Cognitive Changes

Introduction
Most Common Perimenopausal Symptoms that Women Report
Vasomotor Symptoms: Hot Flushes/Night Sweats
Sleep Issues: Insomnia, Decreased Quality of Sleep
Urogenital Symptoms
Mood and Cognition
Bibliography

5 FAQ: Bioidentical Hormones: Compounded and Non-compounded
Introduction
Bibliography

Part II Prescription of HT

6 Transdermal Estrogen as Preferred Prescription for Perimenopausal Symptom Relief, and the Role of Progesterone
Transdermal Estradiol
Contraindications for HT
The Case for Transdermal Estrogen:
The ESTHER Study, 2007
The KEEPS Study, 2012
Bibliography

7 The Significance of Hormone Routes of Administration
Introduction
Routes of Administration
Oral
Vaginal
12 FAQ: Ending HT ........................................................ 89
   Bibliography .................................................................. 91

13 FAQ: HT and Other Conditions: Uterine
   Fibroids, Autoimmune disease, Hypothyroidism,
   and History of Breast Cancer .................................... 93
   Bibliography .................................................................. 95

Part IV The Medical and Cultural History of HT

14 History of HT Use: Controversies and Confusions ................................................. 99
   The First Attempts at Manufacturing Synthetic
   Estrogen (1880s to World War II) ......................... 100
   1930s and 1940s: The Development
   of DES .......................................................................... 101
   1960s: Estrogen Forever and the Promotion
   of HT to Sustain Youthfulness and Femininity ........ 102
   The 1970s: Estrogen Replacement and the Link
   to Uterine/Endometrial Cancer ............................... 103
   1980s: The Pendulum Swings Back—HT
   and the Positive Link to Preventing Osteoporosis ...... 105
   1980s: The Pendulum Swings Back II: HT
   and Protection Against Heart Disease—The Nurses’
   Health Study and the PEPI Trials ............................... 106
      The Nurses’ Health Study ......................................... 106
      PEPI Trials, 1987 ..................................................... 107
   1990s: Heart Disease and Breast Cancer Risks,
   and Increasing Popularity of Prescription .............. 108
      The HERS Study, 1998 ............................................ 108
      HT Linked to Blood Clots, 1996 ............................. 109
   The Women’s Health Initiative, 2002 ..................... 109
   Post-WHI, Post-2002: Results for Hormone
   Therapy ........................................................................ 112
   Conclusions .................................................................. 113
   Bibliography .................................................................. 113
15 The 2002 Women’s Health Initiative Study (WHI): What Did It Prove or Disprove? Future Directions

Introduction ................................................................. 115
Conclusions .................................................................. 117
Bibliography ................................................................ 117

Appendix: Reference Table of HT Brand Names ............ 119

Index ............................................................................ 123
Hormone Therapy
A Clinical Handbook
Sherif, K.
2013, XVII, 127 p. 4 illus., Softcover